Barclays’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-108,800
| Closed | -$10.6M | – | 4912 |
|
|
2021
Q2 | $10.6M | Buy |
+108,800
| New | +$10.4M | 0.01% | 1181 |
|
|
2020
Q2 | – | Sell |
-12,500
| Closed | -$1.08M | – | 6025 |
|
|
2020
Q1 | $1.08M | Buy |
12,500
+3,600
| +40% | +$352K | ﹤0.01% | 2875 |
|
|
2019
Q4 | $957K | Sell |
8,900
-31,700
| -78% | -$3.32M | ﹤0.01% | 3714 |
|
|
2019
Q3 | $3.66M | Sell |
40,600
-2,100
| -5% | -$196K | ﹤0.01% | 2151 |
|
|
2019
Q2 | $3.6M | Sell |
42,700
-11,600
| -21% | -$952K | ﹤0.01% | 2210 |
|
|
2019
Q1 | $4.78M | Buy |
54,300
+9,400
| +21% | +$786K | ﹤0.01% | 1694 |
|
|
2018
Q4 | $3.21M | Sell |
44,900
-34,400
| -43% | -$3.3M | ﹤0.01% | 1944 |
|
|
2018
Q3 | $9.75M | Sell |
79,300
-33,400
| -30% | -$3.79M | 0.01% | 1279 |
|
|
2018
Q2 | $11.1M | Buy |
112,700
+32,800
| +41% | +$2.94M | 0.01% | 1152 |
|
|
2018
Q1 | $6.63M | Sell |
79,900
-51,700
| -39% | -$4.37M | 0.01% | 1426 |
|
|
2017
Q4 | $10.2M | Sell |
131,600
-19,700
| -13% | -$1.34M | 0.01% | 1173 |
|
|
2017
Q3 | $9.27M | Buy |
151,300
+58,800
| +64% | +$3.1M | 0.01% | 1100 |
|
|
2017
Q2 | $4.25M | Buy |
92,500
+81,500
| +741% | +$3.95M | ﹤0.01% | 1592 |
|
|
2017
Q1 | $476K | Sell |
11,000
-181,700
| -94% | -$7.78M | ﹤0.01% | 3445 |
|
|
2016
Q4 | $7.46M | Buy |
192,700
+184,700
| +2,309% | +$8.36M | 0.01% | 1113 |
|
|
2016
Q3 | $405K | Sell |
8,000
-3,100
| -28% | -$154K | ﹤0.01% | 3396 |
|
|
2016
Q2 | $504K | Sell |
11,100
-7,900
| -42% | -$364K | ﹤0.01% | 3208 |
|
|
2016
Q1 | $741K | Sell |
19,000
-124,200
| -87% | -$4.93M | ﹤0.01% | 2788 |
|
|
2015
Q4 | $8.02M | Sell |
143,200
-6,900
| -5% | -$351K | 0.01% | 1007 |
|
|
2015
Q3 | $5.85M | Buy |
150,100
+3,800
| +3% | +$184K | 0.01% | 1261 |
|
|
2015
Q2 | $6.88M | Sell |
146,300
-100
| -0.1% | -$4.24K | 0.01% | 1271 |
|
|
2015
Q1 | $5.71M | Buy |
146,400
+117,500
| +407% | +$4.2M | 0.01% | 1458 |
|
|
2014
Q4 | $636K | Sell |
28,900
-3,500
| -11% | -$66.3K | ﹤0.01% | 3626 |
|
|
2014
Q3 | $486K | Sell |
32,400
-7,600
| -19% | -$114K | ﹤0.01% | 3972 |
|
|
2014
Q2 | $560K | Buy |
40,000
+16,800
| +72% | +$237K | ﹤0.01% | 3864 |
|
|
2014
Q1 | $371K | Buy |
23,200
+14,800
| +176% | +$253K | ﹤0.01% | 4201 |
|
|
2013
Q4 | $76K | Sell |
8,400
-229,200
| -96% | -$2.24M | ﹤0.01% | 5870 |
|
|
2013
Q3 | $2.62M | Buy |
237,600
+198,400
| +506% | +$2.73M | ﹤0.01% | 2286 |
|
|
2013
Q2 | $524K | Buy |
+39,200
| New | +$482K | ﹤0.01% | 4150 |
|
Other funds holding NBIX
VPM
VCM
Barclays's NBIX Position: Q1 2026 in Review
Barclays reduced its Neurocrine Biosciences (NBIX) stake by 3.3% in Q1 2026, selling an estimated $1.1M and leaving 243,984 shares worth $32.1M. The position accounts for 0.01% of the portfolio, ranked #896.
Barclays first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $42.7M in Q3 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Barclays held 243,984 shares of Neurocrine Biosciences worth $32.1M as of Q1 2026.
- Barclays sold 8,257 Neurocrine Biosciences shares in Q1 2026, an estimated $1.1M.
- Neurocrine Biosciences made up 0.01% of Barclays's portfolio in Q1 2026, its #896 holding.
- Barclays first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- Barclays's Neurocrine Biosciences position peaked at $42.7M in Q3 2025.
- 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.